Glaucoma, Stem Cells, and Gene Therapy: Where Are We Now?.

Author: Karim DALIRI ¹ ; Alexander V LJUBIMOV ; Seyedhossein HEKMATIMOGHADDAM
Author Information

1. Neurogenetic Ward, Comprehensive Child Developmental Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Publication Type:Review
Keywords: Ganglion cells; Gene therapy; Glaucoma; Retina; Stem cells
MeSH: Blindness; Genetic Therapy*; Glaucoma*; Regeneration; Retina; Retinal Ganglion Cells; Stem Cells*
From:International Journal of Stem Cells 2017;10(2):119-128
CountryRepublic of Korea
Language:English
Abstract: Glaucoma is the second most common cause of blindness, affecting 70~80 million people around the world. The death of retinal ganglion cells (RGCs) is the main cause of blindness related to this disease. Current therapies do not provide enough protection and regeneration of RGCs. A novel opportunity for treatment of glaucoma is application of technologies related to stem cell and gene therapy. In this perspective we will thus focus on emerging approaches to glaucoma treatment including stem cells and gene therapy.